Syntax Bio
Syntax Bio's discovery platform overcomes the longstanding challenges in stem cell-derived therapies by directly controlling and accelerating cell differentiation.
Syntax Bio is a biotechnology company developing a CRISPR-based platform to accelerate and control the differentiation of induced pluripotent stem cells (iPSCs) into therapeutic-grade cells. Their proprietary "Cellgorithm" technology employs a modified CRISPR system to regulate gene expression in a precise, stepwise manner, mimicking natural developmental processes. This approach aims to overcome limitations of traditional methods by reducing differentiation timelines from months to days, enhancing scalability, and lowering manufacturing costs. Syntax Bio collaborates with biopharmaceutical companies, offering its platform to improve the efficiency and accessibility of cell therapy manufacturing.
Testimonial
Related Companies
Lyric Bio
Pioneering the future of biomanufacturing using proven and proprietary 3D bioprinting and tissue engineering technologies
San Carlos, California
Eywa Biotech
Scaling the production of pharmaceutical-grade psychedelic compounds through synthetic biology
Montevideo, Uruguay · Buenos Aires, Argentina
PrettyLitter
Develops a lightweight cat litter that helps cat owners monitor their pets' health by changing colors in response to abnormalities in urine.
Los Angeles, United States
nVision
nVision’s focus is on women’s health. The company created the first FDA-cleared device for collecting cells from the fallopian tubes, which aimed to enable earlier diagnosis of ovarian cancer. In 2018, nVision was acquired by Boston Scientific.
Herasight
Developing comprehensive embryo screening and guiding parents through IVF using cutting-edge whole genome technologies.
United States
Senodia
MEMS sensors for various applications.
China, Shanghai
Aanika
Innovative science-backed insurance solutions for agriculture and food industries with Bio technology.
Brooklyn, United States
